July 14th, 2025 Bengaluru, India – Anthem Bioscience IPO is finally arrived the company is a leading global CRDMO service provider and has filed an IPO on July 14th, 2025.This is an important milestone for the business, which anticipates the launch of an offer for sale (OFS) that will comprise 5.96 Equity shares of 5.96 crore that will sell for about Rs 3,395 crore. The price range for the IPO is set at Rs540-570 a share. minimum size of the lot is 26 shares, and an investor must pay at least Rs14,820 to take part in the auction for the first share-sale.
Anthem Bioscience IPO Key Dates:
| Event | Date |
|---|---|
| Subscription Opens | July 14, 2025 |
| Subscription Closes | July 16, 2025 |
| Allotment Finalization | July 17, 2025 |
| Refunds Initiated | July 18, 2025 |
| Shares Credited to Demat | July 18, 2025 |
| Listing on NSE & BSE | July 21, 2025 |
Company Overview
It was established in 2006 Anthem Biosciences is a contract research company (CRO) which provides discovery development, manufacturing, and production services to biotech companies as well as the pharmaceutical companies across the world. It operates two research-and-development centers with more than 1,000 researchers in Bengaluru. Anthem provides small and large molecule services including Active Pharmaceutical Ingredients (APIs), biosimilars, probiotics, and specialty ingredients.read more articles like this at News.highzones.com
Financial Performance
Anthem’s numbers have grown steadily over the years:
- FY23 Revenue: ₹1,056.92 crore
- FY24 Revenue: ₹1,419.37 crore
- FY25 Revenue (Estimated): ₹1,800 crore
- Net Profit (FY25): ₹500 crore
- EBITDA Margin: 35%
The company continues to demonstrate a healthy EBITDA margin, driven by efficiency in operations and robust demand for services across its segments.
Anthem Bioscience IPO: Valuation & Peer Comparison
Anthem’s IPO is priced at a Price/Earnings (P/E) ratio of around 71 on the upper price band of ₹570. For comparison, peers such as Syngene International and Divi’s Laboratories trade at P/E multiples of 51-147. This is where Anthem is at in comparison to others in the industry. read more business and finance related stories at News.highzones.com
Risk Factors
Investors should consider the following risks:.
- Regulatory challenge The pharma industry is highly regulated, which could limit operations.
- Competition: may be subject to competitive forces that affect market share.
- Operational Hurdles: Scaling operations to supply the world market is hard to do logistically.
Grey Market Premium (GMP)
As on 14th July 2025, the GMP is ₹97 which is a 17% premium over the upper band of ₹570. This is an indication of investor confidence before the listing yet to be announced.read more articles like this at News.highzones.com
IPO Details at a Glance
| Feature | Details |
|---|---|
| Issue Type | Offer for Sale (OFS) |
| Issue Size | ₹3,395 crore |
| Price Band | ₹540 – ₹570 |
| Lot Size | 26 shares |
| Minimum Investment | ₹14,820 |
| Listing Exchanges | NSE, BSE |
| Tentative Listing Date | July 21, 2025 |
🔮 Performance Outlook
Return Since IPO Considering Anthem’s solid financials, strategic global partnerships and strong market position, the IPO seems like a good long-term investment. The high margin specialized services story of the company gives it the basis for continued growth. However, investors who are considering investing should take into consideration the risks associated with investing before making a decision to invest.
🚀 Upcoming IPOs to Watch
| Company Name | Industry | Expected IPO Date | Estimated Issue Size |
|---|---|---|---|
| Monika Alcobev | Beverages | July 2025 | ₹500 crore |
| Elitecon International | Real Estate | August 2025 | ₹700 crore |
| Schloss Bangalore | Real Estate | September 2025 | ₹600 crore |
Investor Takeaway
Anthem Biosciences’ IPO provides investment opportunity in a leading CRDMO with robust growth opportunities. Although the valuation looks cheap when compared to industry peers, investors should be mindful of the risks and do some deep blue water research before subscribing.
Anthem Bioscience IPO: FAQs
It’s an opportunity to purchase shares of Anthem Biosciences, a leading CRDMO with its headquarters in Bengaluru.
The IPO begins the day of July 14 2025 The IPO closes on July 16, 2025..
The price range is somewhere between between Rs540 to Rs570 per share.
Anthem has solid financials, however it faces the risk of regulatory and competitive issues.
Important risks include regulatory challenges competitive market, regulatory challenges, along with operational expansion.
The GMP is Rs97, representing a 17% increase over the higher price band.
The shares are expected to be traded on July 21, 2025..
You can submit your application through an online broker or stock broker platforms that accept IPO applications.
The company has been able to show consistent sales growth, and has a solid EBITDA ratio of around 35 percent.
Anthem hopes to raise a total of 395 crore through the IPO.
Disclaimer:
We did not write the contents of this article and cannot guarantee their accuracy. We strongly advise readers to consult an investment advisor before making any investment decisions.The information came from open sources and is based on the views of the author at the date of publication. Market conditions are subject to alter, and any investment has risks.The website does not accept any liability or responsibility for any damages or losses resulting from the information provided on it.
If you’ve found this piece and the opinion of the author helpful, you can take a look at the News.highzones.com Check out our website for the latest news and market analysis from experts on investment, finance and retirement.